PH12021552967A1 - Treatments of angioedema - Google Patents

Treatments of angioedema

Info

Publication number: PH12021552967A1
Authority: PH; Philippines
Prior art keywords: treatments; angioedema; aenh; hereditary; demand
Prior art date: 2019-06-14

Application number

PH1/2021/552967A

Other languages

English (en)

Inventor

Edward Paul Feener

Andreas Maetzel

Sally Louise Marsh

Michael David Smith

Christopher Martyn Yea

Original Assignee

Kalvista Pharmaceuticals Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2019-06-14

Filing date

2020-06-15

Publication date

2022-07-25

2020-06-15 Application filed by Kalvista Pharmaceuticals Ltd filed Critical Kalvista Pharmaceuticals Ltd

2022-07-25 Publication of PH12021552967A1 publication Critical patent/PH12021552967A1/en

Links

208000028185 Angioedema Diseases 0.000 title abstract 4
238000011282 treatment Methods 0.000 title abstract 4
101800004538 Bradykinin Proteins 0.000 abstract 2
QXZGBUJJYSLZLT-UHFFFAOYSA-N H-Arg-Pro-Pro-Gly-Phe-Ser-Pro-Phe-Arg-OH Natural products NC(N)=NCCCC(N)C(=O)N1CCCC1C(=O)N1C(C(=O)NCC(=O)NC(CC=2C=CC=CC=2)C(=O)NC(CO)C(=O)N2C(CCC2)C(=O)NC(CC=2C=CC=CC=2)C(=O)NC(CCCN=C(N)N)C(O)=O)CCC1 QXZGBUJJYSLZLT-UHFFFAOYSA-N 0.000 abstract 2
102100035792 Kininogen-1 Human genes 0.000 abstract 2
QXZGBUJJYSLZLT-FDISYFBBSA-N bradykinin Chemical compound NC(=N)NCCC[C@H](N)C(=O)N1CCC[C@H]1C(=O)N1[C@H](C(=O)NCC(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CO)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)CCC1 QXZGBUJJYSLZLT-FDISYFBBSA-N 0.000 abstract 2
230000001404 mediated effect Effects 0.000 abstract 2
229940126155 plasma kallikrein inhibitor Drugs 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/10—Antioedematous agents; Diuretics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Veterinary Medicine (AREA)
Chemical & Material Sciences (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Epidemiology (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Organic Chemistry (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Pulmonology (AREA)
Immunology (AREA)
Physiology (AREA)
Nutrition Science (AREA)
Vascular Medicine (AREA)
Diabetes (AREA)
Hematology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Peptides Or Proteins (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)

PH1/2021/552967A 2019-06-14 2020-06-15 Treatments of angioedema PH12021552967A1 (en)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US201962861758P	2019-06-14	2019-06-14
GBGB1910125.2A GB201910125D0 (en)	2019-07-15	2019-07-15	Treatments of angioedema
PCT/GB2020/051441 WO2020249979A1 (fr)	2019-06-14	2020-06-15	Traitements de l'oedème de quincke

Publications (1)

Publication Number	Publication Date
PH12021552967A1 true PH12021552967A1 (en)	2022-07-25

Family

ID=67700187

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
PH1/2021/552967A PH12021552967A1 (en)	2019-06-14	2020-06-15	Treatments of angioedema

Country Status (18)

Country	Link
US (1)	US20220226293A1 (fr)
EP (1)	EP3982961A1 (fr)
JP (1)	JP7640474B2 (fr)
KR (1)	KR20220024221A (fr)
CN (2)	CN118078821A (fr)
AR (1)	AR119159A1 (fr)
AU (1)	AU2020293616A1 (fr)
BR (1)	BR112021024447A2 (fr)
CA (1)	CA3142220A1 (fr)
CL (2)	CL2021003243A1 (fr)
GB (1)	GB201910125D0 (fr)
IL (1)	IL288612A (fr)
MA (1)	MA56188A (fr)
MX (1)	MX2021014558A (fr)
PH (1)	PH12021552967A1 (fr)
SG (1)	SG11202113375PA (fr)
TW (1)	TW202112371A (fr)
WO (1)	WO2020249979A1 (fr)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB201609607D0 (en)	2016-06-01	2016-07-13	Kalvista Pharmaceuticals Ltd	Polymorphs of N-(3-Fluoro-4-methoxypyridin-2-yl)methyl)-3-(methoxymethyl)-1-({4-((2-oxopy ridin-1-yl)methyl)phenyl}methyl)pyrazole-4-carboxamide and salts
GB201719881D0 (en)	2017-11-29	2018-01-10	Kalvista Pharmaceuticals Ltd	Solid forms of plasma kallikrein inhibitor and salts thereof
CN114206852A (zh)	2019-08-09	2022-03-18	卡尔维斯塔制药有限公司	血浆激肽释放酶抑制剂
CA3255900A1 (fr)	2022-04-27	2023-11-02	Kalvista Pharmaceuticals Limited	Formulations d'un inhibiteur de la kallicréine plasmatique
CN116003386B (zh) *	2022-11-20	2024-03-26	药康众拓(北京)医药科技有限公司	一种氘代n-苄基吡啶酮吡唑甲酰胺类化合物、药物组合物和用途

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5187157A (en)	1987-06-05	1993-02-16	Du Pont Merck Pharmaceutical Company	Peptide boronic acid inhibitors of trypsin-like proteases
GB9019558D0 (en)	1990-09-07	1990-10-24	Szelke Michael	Enzyme inhibitors
SE9301911D0 (sv)	1993-06-03	1993-06-03	Ab Astra	New peptide derivatives
US5589467A (en)	1993-09-17	1996-12-31	Novo Nordisk A/S	2,5',N6-trisubstituted adenosine derivatives
GB0205527D0 (en)	2002-03-08	2002-04-24	Ferring Bv	Inhibitors
US7429604B2 (en)	2004-06-15	2008-09-30	Bristol Myers Squibb Company	Six-membered heterocycles useful as serine protease inhibitors
JP5322935B2 (ja)	2006-07-31	2013-10-23	アクティベサイトファーマシューティカルズインコーポレイティッド	血漿カリクレインの阻害薬
DE102006050672A1 (de)	2006-10-24	2008-04-30	Curacyte Discovery Gmbh	Hemmstoffe des Plasmins und des Plasmakallikreins
JP2013121919A (ja)	2010-03-25	2013-06-20	Astellas Pharma Inc	血漿カリクレイン阻害剤
ES2483802T3 (es)	2010-07-07	2014-08-07	The Medicines Company (Leipzig) Gmbh	Inhibidores de serina proteasa
WO2012009009A2 (fr)	2010-07-14	2012-01-19	Addex Pharma S.A.	Nouveaux dérivés de 2-amino-4-pyrazolyl-thiazole et leur utilisation en tant que modulateurs allostériques des récepteurs métabotropiques du glutamate
US9290485B2 (en)	2010-08-04	2016-03-22	Novartis Ag	N-((6-amino-pyridin-3-yl)methyl)-heteroaryl-carboxamides
GB2494851A (en)	2011-07-07	2013-03-27	Kalvista Pharmaceuticals Ltd	Plasma kallikrein inhibitors
GB201300304D0 (en)	2013-01-08	2013-02-20	Kalvista Pharmaceuticals Ltd	Benzylamine derivatives
ES2909885T3 (es)	2013-05-23	2022-05-10	Kalvista Pharmaceuticals Ltd	Inhibidores de la calicreína plasmática
EP2886107A1 (fr) *	2013-12-17	2015-06-24	ObsEva S.A.	Formules orales de dérivés de pyrrolydine
GB201421083D0 (en)	2014-11-27	2015-01-14	Kalvista Pharmaceuticals Ltd	Enzyme inhibitors
GB201609607D0 (en) *	2016-06-01	2016-07-13	Kalvista Pharmaceuticals Ltd	Polymorphs of N-(3-Fluoro-4-methoxypyridin-2-yl)methyl)-3-(methoxymethyl)-1-({4-((2-oxopy ridin-1-yl)methyl)phenyl}methyl)pyrazole-4-carboxamide and salts
GB201721515D0 (en) *	2017-12-21	2018-02-07	Kalvista Pharmaceuticals Ltd	Dosage forms comprising a plasma kallikrein inhibtor
IL274557B2 (en) *	2017-11-29	2024-09-01	Kalvista Pharmaceuticals Ltd	Dosage forms comprising a plasma kallikrein inhibitor

2019
- 2019-07-15 GB GBGB1910125.2A patent/GB201910125D0/en not_active Ceased
2020
- 2020-06-15 BR BR112021024447A patent/BR112021024447A2/pt unknown
- 2020-06-15 TW TW109120109A patent/TW202112371A/zh unknown
- 2020-06-15 WO PCT/GB2020/051441 patent/WO2020249979A1/fr not_active Ceased
- 2020-06-15 CN CN202410143627.6A patent/CN118078821A/zh active Pending
- 2020-06-15 MA MA056188A patent/MA56188A/fr unknown
- 2020-06-15 MX MX2021014558A patent/MX2021014558A/es unknown
- 2020-06-15 CA CA3142220A patent/CA3142220A1/fr active Pending
- 2020-06-15 JP JP2021571935A patent/JP7640474B2/ja active Active
- 2020-06-15 SG SG11202113375PA patent/SG11202113375PA/en unknown
- 2020-06-15 AU AU2020293616A patent/AU2020293616A1/en not_active Abandoned
- 2020-06-15 CN CN202080043658.4A patent/CN113993520A/zh active Pending
- 2020-06-15 PH PH1/2021/552967A patent/PH12021552967A1/en unknown
- 2020-06-15 EP EP20734285.8A patent/EP3982961A1/fr not_active Withdrawn
- 2020-06-15 KR KR1020217043375A patent/KR20220024221A/ko not_active Withdrawn
- 2020-06-15 US US17/617,456 patent/US20220226293A1/en not_active Abandoned
- 2020-06-16 AR ARP200101682A patent/AR119159A1/es not_active Application Discontinuation
2021
- 2021-12-02 IL IL288612A patent/IL288612A/en unknown
- 2021-12-06 CL CL2021003243A patent/CL2021003243A1/es unknown
2023
- 2023-03-10 CL CL2023000699A patent/CL2023000699A1/es unknown

Also Published As

Publication number	Publication date
KR20220024221A (ko)	2022-03-03
CA3142220A1 (fr)	2020-12-17
SG11202113375PA (en)	2021-12-30
EP3982961A1 (fr)	2022-04-20
GB201910125D0 (en)	2019-08-28
TW202112371A (zh)	2021-04-01
MA56188A (fr)	2022-04-20
AR119159A1 (es)	2021-12-01
CN118078821A (zh)	2024-05-28
AU2020293616A1 (en)	2022-01-27
JP7640474B2 (ja)	2025-03-05
WO2020249979A1 (fr)	2020-12-17
CN113993520A (zh)	2022-01-28
JP2022537913A (ja)	2022-08-31
MX2021014558A (es)	2022-04-06
CL2021003243A1 (es)	2022-09-30
US20220226293A1 (en)	2022-07-21
CL2023000699A1 (es)	2023-10-30
IL288612A (en)	2022-02-01
BR112021024447A2 (pt)	2022-01-18

Publication	Publication Date	Title
ZA202110685B (en)	2024-06-26	Treatments of hereditary angioedema
PH12021552967A1 (en)	2022-07-25	Treatments of angioedema
PH12021552497A1 (en)	2023-02-27	Enzyme inhibitors
ZA201606320B (en)	2025-03-26	Human plasma kallikrein inhibitors
ZA201705749B (en)	2024-12-18	Substituted pyrazole compounds as serine protease inhibitors
MX2020005484A (es)	2020-08-27	Formas solidas de un inhibidor de calicreina en plasma y sales del mismo.
HK1252937A1 (zh)	2019-06-06	用於治疗抑郁症的方法和试剂盒
MX379621B (es)	2025-03-11	Combinacion de inhibidor de bcl-2 e inhibidor de mek para el tratamiento de cancer
PH12018500678A1 (en)	2018-10-01	Human plasma kallikrein inhibitors
PH12022550130A1 (en)	2022-11-14	Enzyme inhibitors
EP4663247A3 (fr)	2026-03-04	Formulations/compositions comprenant un inhibiteur de btk
PH12019500758A1 (en)	2019-07-24	Pharmaceutical compositions and methods for the treatment of cancer
WO2019098811A3 (fr)	2019-07-11	Composition pour prévenir, soulager ou traiter des maladies de perte osseuse, comprenant cyclo(his-pro) (chp)
WO2020109233A3 (fr)	2020-07-23	Inhibiteurs de trmt2a utilisés pour le traitement de maladies à polyglutamine
EP4234022A3 (fr)	2023-10-04	Bétahistine, ou un sel pharmaceutiquement acceptable de celle-ci, et un inhibiteur de monoamine oxydase, destinés à être utilisés dans le traitement ou la prévention d'un ou plusieurs symptômes de vertige chez un sujet
PH12020551331A1 (en)	2021-09-06	Treatment and prevention of pre-eclampsia
MX2020011912A (es)	2021-01-29	Terapia de combinacion para el tratamiento del virus de la hepatitis c (vhc).
MX2021009663A (es)	2021-09-08	Tratamiento del sindrome de pitt-hopkins.
MX2021008887A (es)	2021-08-19	Minociclina para el tratamiento del sindrome de pitt-hopkins.
MX2016011002A (es)	2017-08-10	Tratamiento de angioedema hereditario con inhibidor c1.
PH12017501918A1 (en)	2018-03-19	Multi-peptide composition
WO2022106984A3 (fr)	2022-07-07	Inhibiteurs à petites molécules de protéase principale de sars-cov2
EP4681778A3 (fr)	2026-03-25	Polythérapies à base d'inhibiteurs de pd1 et il-17b
NZ780408A (en)	2024-12-20	Human plasma kallikrein inhibitors